Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,937
datasets available to search
ShareScore release 0.9.0
Dataset results
2,937 results for “Multiple Myeloma”
Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
ClinicalTrials.gov study NCT00378209. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma
ClinicalTrials.gov study NCT03944057. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma
ClinicalTrials.gov study NCT04097301. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma
ClinicalTrials.gov study NCT00724568. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
ClinicalTrials.gov study NCT03110562. IPD Sharing: UNDECIDED. Countries: 21. Publications: 7.
Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
ClinicalTrials.gov study NCT01832727. IPD Sharing: Not stated. Countries: 2. Publications: 1.
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for
ClinicalTrials.gov study NCT03652064. IPD Sharing: Not stated. Countries: 13. Publications: 1.
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontl
ClinicalTrials.gov study NCT03901963. IPD Sharing: YES. Countries: 2. Publications: 2.
Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma
ClinicalTrials.gov study NCT01319422. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
ClinicalTrials.gov study NCT02046070. IPD Sharing: YES. Countries: 5. Publications: 2.
Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma
ClinicalTrials.gov study NCT03733717. IPD Sharing: YES. Countries: 1. Publications: 1.
A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients
ClinicalTrials.gov study NCT00911859. IPD Sharing: Not stated. Countries: 11. Publications: 1.
Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
ClinicalTrials.gov study NCT00609167. IPD Sharing: Not stated. Countries: 2. Publications: 2.
Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma
ClinicalTrials.gov study NCT00932698. IPD Sharing: YES. Countries: 1. Publications: 2.
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
ClinicalTrials.gov study NCT01380145. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov study NCT03548207. IPD Sharing: Not stated. Countries: 2. Publications: 11.
Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov study NCT00445484. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma
ClinicalTrials.gov study NCT00179647. IPD Sharing: Not stated. Countries: 2. Publications: 1.
A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
ClinicalTrials.gov study NCT03301220. IPD Sharing: Not stated. Countries: 24. Publications: 1.
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
ClinicalTrials.gov study NCT01345019. IPD Sharing: YES. Countries: 29. Publications: 4.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.